Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL227484

CCCC[N+](CCCC)(CCCC)CCCC.N#C[S-]

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 4/20 0.67
SLC22A2 O15244 1/20 0.58
ALDH1A1 P00352 1/20 0.52
TP53 P04637 1/20 0.52
CYP3A4 P08684 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
ALOX12 P18054 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
HSD17B10 Q99714 1/20 0.52
DNM1 Q05193 6/20 0.48
APAF1 O14727 1/20 0.40
HSP90AA1 P07900 1/20 0.40
RAD52 P43351 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL5953813 1.00 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL31130637 0.97 SLC22A1 (0.63) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Thiocyanic Acid SCHEMBL6461784 0.95 SLC22A1 (0.65) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrapentylammonium SCHEMBL306449 0.94 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL3944134 0.93 SLC22A1 (0.57) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrahexylammonium SCHEMBL11425178 0.92 SLC22A1 (0.68) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Thiocyanic Acid SCHEMBL15008885 0.92 SLC22A1 (0.68) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Thiocyanic Acid SCHEMBL16414512 0.89 SLC22A1 (0.52) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL15822811 0.86 SLC22A1 (0.71) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL3414877 0.85 SLC22A1 (0.92) SLC22A1SLC22A2ALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739727-A1 CURING AGENT COMPOSITION COMPRISING SALTS OF THIOCYANATE Hilti Aktiengesellschaft (LI) 2026-05-13 EP claimed
US-20260045538-A1 Catalyst for Lithium-Sulfur Batteries UNIV NORTHEASTERN (US) 2026-02-12 US claimed
WO-2025011861-A1 CURING AGENT COMPOSITION COMPRISING SALTS OF THIOCYANATE HILTI AKTIENGESELLSCHAFT (LI) 2025-01-16 WO claimed
EP-4488315-A1 CURING AGENT COMPOSITION COMPRISING SALTS OF THIOCYANATE Hilti Aktiengesellschaft (LI) 2025-01-08 EP claimed
CN-118414064-A Preparation method and application of 1D/3D halide perovskite gradient heterojunction 华南理工大学 2024-07-30 CN claimed
CN-117164875-A Preparation method of tubular metal copper phthalocyanine polymer and cyclic carbonate 浙江理工大学 2023-12-05 CN claimed
CN-116836480-A Flame-retardant polypropylene composite plastic and manufacturing process thereof 合肥徽润涂料有限公司 2023-10-03 CN claimed
CN-112457272-B Preparation method of (3-methoxy-1, 2, 4-thiadiazole-5-amino) phenyl formate 上海再启生物技术有限公司 2022-04-19 CN claimed
CN-112457272-A Preparation method of (3-methoxy-1, 2, 4-thiadiazole-5-amino) phenyl formate 上海再启生物技术有限公司 2021-03-09 CN claimed
US-10784388-B2 Photovoltaic devices with depleted heterojunctions and shell-passivated nanoparticles THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2020-09-22 US claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5532082-A LITHIUM CATIONS WITH SOLVENTS AND THIOCYANATE ANIONS VALENCE TECHNOLOGY, INC. 1996-07-02 US claimed
US-5527927-A CATALYTIC TRANSESTERIFICATION OF GLYCIDOL AND METHYL METHACRYLATE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1996-06-18 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
WO-1996007916-A1 ACETIC ANHYDRIDE ACTIVATION FOR C-TERMINAL PROTEIN SEQUENCING THE PERKIN-ELMER CORPORATION (US) 1996-03-14 WO claimed
EP-0683163-A1 Process for producing glycidyl acrylate or glycidyl methacrylate MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1995-11-22 EP claimed
US-5468843-A Acetic anhydride activation for C-terminal protein sequencing PERKIN-ELMER (US) 1995-11-21 US claimed
US-5068386-A PREPARATION OF TERTIARY-HYDROCARBYLSILYL COMPOUNDS DOW CORNING TORAY SILICONE COMPANY, LTD. (JP) 1991-11-26 US claimed
EP-0405560-A2 Preparation of tertiary-hydrocarbylsilyl compounds Dow Corning Toray Silicone Company, Limited (JP) 1991-01-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260045538-A1 Catalyst for Lithium-Sulfur Batteries KCNA4, CACNA2D4, KCNA1 SLC22A1 799/4885SLC22A2 835/4885ALDH1A1 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.